Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies
Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics. ZB716 was found to have high plasma protein binding in human and animal plasma,...
Main Authors: | Jiawang Liu, Nirmal Rajasekaran, Ahamed Hossain, Changde Zhang, Shanchun Guo, Borui Kang, Hunsoon Jung, Hongjoong Kim, Guangdi Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/719 |
Similar Items
-
Functional validation of ZbFAD2 and ZbFAD3 in the alkylamide biosynthesis pathway from Zanthoxylum bungeanum Maxim
by: Jie Zhang, et al.
Published: (2022-09-01) -
Whitefly-Transmitted Cucurbit Leaf Crumple Virus in Florida
by: Susan E. Webb, et al.
Published: (2007-04-01) -
A method to detect fulvestrant interference in estradiol in breast cancer patients
by: Margarida Brito, et al.
Published: (2023-10-01) -
Good Worker Health and Hygiene Practices: Evaluation and Importance in GAPs and GMPs
by: Melissa Holmes-Pearce, et al.
Published: (2004-12-01) -
Fulvestrant in treatment for metastatic breast cancer
by: L. Yu. Vladimirova, et al.
Published: (2019-12-01)